- Correction
- Open access
- Published:
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
BMC Cancer volume 24, Article number: 563 (2024)
The Original Article was published on 08 April 2024
Correction to: BMC Cancer 24, 436 (2024)
Following publication of the original article [1], the authors reported an error in the funding section of their article. The correct funding statement is:
The present study is an investigator-driven trial, carried out by participating clinicians, who have the intellectual ownership of the results. The study is sponsored by Gruppo Oncologico del Nord Ovest, Cooperative Group having its headquarters at Via G. Mameli, 3–16,122 Genoa (ITALY) and funded by GONO Foundation. Part of the funding is also provided by Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, through institutional funds and a nonconditional support of Fondazione Anna Villa e Felice Rusconi Onlus. This project is also in collaboration with Intesa Sanpaolo S.p.A. No funds can be provided to ethical committees and single participating centers. The study will be conducted according to the current regulations.
References
Niger M, Nichetti F, Fornaro L, et al. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer. 2024;24:436. https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-024-12225-6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-024-12225-6.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Niger, M., Nichetti, F., Fornaro, L. et al. Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer 24, 563 (2024). https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-024-12328-0
Published:
DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-024-12328-0